{
  "source": "PA-Notification-Xeljanz.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1116-19\nProgram Prior Authorization/Notification\nMedication Xeljanz®/Xeljanz® XR/Xeljanz® Oral Solution (tofacitinib)\nP&T Approval Date 11/2012, 2/2013, 2/2014, 2/2015, 3/2016, 3/2017, 2/2018, 7/2018,\n7/2019, 9/2019, 2/2020, 11/2020, 11/2021, 2/2022, 2/2023, 7/2023,\n9/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nXeljanz/Xeljanz XR (tofacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment\nof adult patients with moderately to severely active rheumatoid arthritis, active psoriatic\narthritis, ankylosing spondylitis and moderately to severely active ulcerative colitis, who have\nhad an inadequate response or intolerance to one or more TNF blockers. Xeljanz/Xeljanz Oral\nSolution is indicated for the treatment of active polyarticular course juvenile idiopathic\narthritis in patients 2 years of age and older who have had an inadequate response or\nintolerance to one or more TNF blockers.\nLimitations of Use:\nThe use of Xeljanz/Xeljanz XR/Xeljanz Oral Solution in combination with biologic\nDMARDs, biologic therapies for UC or potent immunosuppressants such as azathioprine and\ncyclosporine is not recommended.\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Xeljanz or Xeljanz XR will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active RA\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor\n-AND-\n(3) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq\n(upadacitinib), Olumiant (baricitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\n© 2024 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Xeljanz or Xeljanz XR will be",
    ") Potent immunosuppressant (e.g., azathioprine or cyclosporine)\n© 2024 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Xeljanz or Xeljanz XR will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Xeljanz or Xeljanz XR therapy\n-AND-\n(2) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq\n(upadacitinib), Olumiant (baricitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Xeljanz or Xeljanz XR will be approved based on all of the following criteria:\n(1) Diagnosis of active PsA\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor\n-AND-\n(3) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx\n(secukinumab), Taltz (ixekizumab), Rinvoq (upadacitinib), Olumiant\n(baricitinib), Otezla (apremilast)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\n2. Reauthorization\na. Xeljanz or Xeljanz XR will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Xeljanz or Xeljanz XR therapy\n-AND-\n(2) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Skyrizi ",
    "tion with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx\n(secukinumab), Taltz (ixekizumab), Rinvoq (upadacitinib), Olumiant\n(baricitinib), Otezla (apremilast)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\nC. Ulcerative Colitis (UC)\n1. Initial Authorization\na. Xeljanz or Xeljanz XR will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active UC\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor\n-AND-\n(3) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq\n(upadacitinib), Olumiant (baricitinib), Stelara (ustekinumab), Skyrizi\n(risankizumab)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Xeljanz or Xeljanz XR will be approved based on both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n3\n(1) Documentation of positive clinical response to Xeljanz or Xeljanz XR therapy\n-AND-\n(2) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq\n(upadacitinib), Olumiant (baricitinib), Stelara (ustekinumab), Skyrizi\n(risankizumab)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\nD. Ankylosing Spondylitis\n1. Initial Authorization\na. Xeljanz or Xeljanz XR will be approved based on all of the foll",
    ", cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\nD. Ankylosing Spondylitis\n1. Initial Authorization\na. Xeljanz or Xeljanz XR will be approved based on all of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor\n-AND-\n(3) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq\n(upadacitinib), Olumiant (baricitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Xeljanz or Xeljanz XR will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Xeljanz or Xeljanz XR therapy\n-AND-\n(2) Patient is not receiving Xeljanz or Xeljanz XR in combination with either of the\n© 2024 UnitedHealthcare Services, Inc.\n4\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Rinvoq\n(upadacitinib), Olumiant (baricitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\nE. Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)\n1. Initial Authorization\na. Xeljanz or Xeljanz Oral Solution will be approved based on both of the following\ncriteria:\n(1) Diagnosis of active polyarticular course juvenile idiopathic arthritis\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor\n-AND-\n(3) Patient is not receiving Xeljanz or Xeljanz Oral Solution in combination with\neither of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimum",
    "or Xeljanz Oral Solution in combination with\neither of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Xeljanz or Xeljanz Oral Solution will be approved based on both of the following\ncriteria:\n(1) Documentation of positive clinical response to Xeljanz or Xeljanz Oral Solution\ntherapy\n-AND-\n(2) Patient is not receiving Xeljanz or Xeljanz Oral Solution in combination with\neither of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\n© 2024 UnitedHealthcare Services, Inc.\n5\nSimponi (golimumab), Orencia (abatacept), adalimumab, Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Xeljanz/Xeljanz XR/Xeljanz Oral Solution [package insert]. New York, NY: Pfizer Labs;\nMay 2024.\nProgram Prior Authorization/Notification – Xeljanz/Xeljanz XR/Xeljanz Oral\nSolution (tofacitinib)\nChange Control\n2/2014 Changed methotrexate failure criterion to standard verbiage.\nReauthorization criteria revised to include concomitant therapy criteria.\n",
    "anz XR/Xeljanz Oral\nSolution (tofacitinib)\nChange Control\n2/2014 Changed methotrexate failure criterion to standard verbiage.\nReauthorization criteria revised to include concomitant therapy criteria.\nExtended reauthorization duration to 24 months.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n2/2015 Annual review with no change to coverage criteria. Minor reformatting.\nUpdated clinical rules, background and references.\n3/2016 Annual review with minor formatting changes to the coverage criteria\nwith no changes to the clinical intent. Added Xeljanz XR to criteria.\nUpdated reference.\n3/2017 Annual review with no change to coverage criteria. Updated\nreferences.\n3/2018 Administrative change to adjust Oxford effective date.\n2/2018 Added psoriatic arthritis to the coverage rationale. Updated references.\n7/2018 Added ulcerative colitis to the coverage rationale. Updated references.\n7/2019 Annual review with no changes to the coverage criteria. Updated\nbackground.\n9/2019 Updated coverage rationale for ulcerative colitis to align with\nprescribing information. Updated background and references.\n2/2020 Added Xeljanz XR to the ulcerative colitis section due to expanded\nindication for use. Updated background and references.\n11/2020 Updated background and criteria due to new indication for polyarticular\njuvenile idiopathic arthritis. Changed all reauthorization durations to 12\n© 2024 UnitedHealthcare Services, Inc.\n6\nmonths and removed concomitant use with PDE4 inhibitor in UC\nsection to align with related programs. Updated references.\n11/2021 Annual review. Added Rinvoq as example of JAK inhibitor in RA\nsection. Updated background and reference.\n2/2022 Added step through a TNF inhibitor for RA, PsA and pcJIA per updated\nlabel. Updated language in step through TNF inhibitor for UC. Added\ncoverage criteria for new indication, ankylosing spondylitis. Updated\nbackground and references.\n2/2023 Annual review. Updated listed examples from Humira ",
    " in step through TNF inhibitor for UC. Added\ncoverage criteria for new indication, ankylosing spondylitis. Updated\nbackground and references.\n2/2023 Annual review. Updated listed examples from Humira to adalimumab.\nUpdated reference. Added state mandate footnote.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n9/2023 Updated examples. No change to coverage criteria.\n10/2024 Annual review with no change to criteria. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n7"
  ]
}